• 1992

Company Description

Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.

Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). They believe that Arbutus' comprehensive HBV pipeline of drugs and drug candidates optimally positions us to transform the HBV treatment landscape and to capitalize on the HBV global market opportunity. They are developing a portfolio of drug candidates with multiple mechanisms of action that They believe will result in a combination therapy to cure HBV. Specifically, They seek to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence.